[
  {
    "ts": null,
    "headline": "Tracking AMG's Yacktman Asset Management Portfolio - Q1 2025 Update",
    "summary": "Read here for Yacktman's Q1 2025 portfolio trends, top holdings, stake changes, and strategies with highlights on Canadian Natural Resources & PepsiCo.",
    "url": "https://finnhub.io/api/news?id=36a8a56c2d2d6f00a78a6b4f9d508bf30461e0432094acffab2700fd67a431ea",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746055924,
      "headline": "Tracking AMG's Yacktman Asset Management Portfolio - Q1 2025 Update",
      "id": 134165461,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Read here for Yacktman's Q1 2025 portfolio trends, top holdings, stake changes, and strategies with highlights on Canadian Natural Resources & PepsiCo.",
      "url": "https://finnhub.io/api/news?id=36a8a56c2d2d6f00a78a6b4f9d508bf30461e0432094acffab2700fd67a431ea"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Reports for Amazon.com, Johnson & Johnson & Cisco Systems",
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Johnson & Johnson (JNJ) and Cisco Systems, Inc. (CSCO), as well as a micro-cap NeurAxis, Inc. (NRXS).",
    "url": "https://finnhub.io/api/news?id=c093f1335c7912e26ecda027ce068191992e96550f94d1685875a269a6a5c236",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746046920,
      "headline": "Top Stock Reports for Amazon.com, Johnson & Johnson & Cisco Systems",
      "id": 134165744,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Johnson & Johnson (JNJ) and Cisco Systems, Inc. (CSCO), as well as a micro-cap NeurAxis, Inc. (NRXS).",
      "url": "https://finnhub.io/api/news?id=c093f1335c7912e26ecda027ce068191992e96550f94d1685875a269a6a5c236"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ): Jim Cramer Says “They Love the Weak Dollar” — Is This Quiet Giant Back in Favor?",
    "summary": "We recently published a list of Jim Cramer Reveals Details Of Trump’s Tariff Negotiations & Discusses 10 Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discusses. In his recent appearance on CNBC’s Squawk on the Street, Jim Cramer commented […]",
    "url": "https://finnhub.io/api/news?id=e65ef0cdf1ac83c487d7c93873f07afaca9f0d0bc63cbeee1e3a988334b75e58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746044228,
      "headline": "Johnson & Johnson (JNJ): Jim Cramer Says “They Love the Weak Dollar” — Is This Quiet Giant Back in Favor?",
      "id": 134165931,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer Reveals Details Of Trump’s Tariff Negotiations & Discusses 10 Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discusses. In his recent appearance on CNBC’s Squawk on the Street, Jim Cramer commented […]",
      "url": "https://finnhub.io/api/news?id=e65ef0cdf1ac83c487d7c93873f07afaca9f0d0bc63cbeee1e3a988334b75e58"
    }
  },
  {
    "ts": null,
    "headline": "Is Johnson & Johnson (JNJ) the Best Dow Stock for the Next 12 Months?",
    "summary": "We recently published a list of The Best and Worst Dow Stocks for the Next 12 Months. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best and worst dow stocks for the next 12 months. The Dow Jones Industrial Average (DJIA), or the Dow, […]",
    "url": "https://finnhub.io/api/news?id=4a34067628fa1c46a0a2e8fbae72f399391e2f71a8d200867c2bf4dc536d19cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746037697,
      "headline": "Is Johnson & Johnson (JNJ) the Best Dow Stock for the Next 12 Months?",
      "id": 134165932,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published a list of The Best and Worst Dow Stocks for the Next 12 Months. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best and worst dow stocks for the next 12 months. The Dow Jones Industrial Average (DJIA), or the Dow, […]",
      "url": "https://finnhub.io/api/news?id=4a34067628fa1c46a0a2e8fbae72f399391e2f71a8d200867c2bf4dc536d19cf"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (NYSE:JNJ) Gains FDA Approval For IMAAVY™ To Treat Myasthenia Gravis",
    "summary": "Johnson & Johnson (NYSE:JNJ) recently experienced a 3% price increase in the last quarter, a period during which significant developments occurred for the company. Notably, the FDA granted approval for IMAAVY, a new monoclonal antibody treatment for generalized myasthenia gravis, potentially strengthening J&J's portfolio in autoimmune conditions. Additionally, their Q1 earnings report highlighted a substantial increase in net income and an increased quarterly dividend, marking the 63rd...",
    "url": "https://finnhub.io/api/news?id=af0fe83484030cbe6511ab509f66026ce1c5ed43f4fb9c2bccae9aded3cfaff2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746034251,
      "headline": "Johnson & Johnson (NYSE:JNJ) Gains FDA Approval For IMAAVY™ To Treat Myasthenia Gravis",
      "id": 134165933,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) recently experienced a 3% price increase in the last quarter, a period during which significant developments occurred for the company. Notably, the FDA granted approval for IMAAVY, a new monoclonal antibody treatment for generalized myasthenia gravis, potentially strengthening J&J's portfolio in autoimmune conditions. Additionally, their Q1 earnings report highlighted a substantial increase in net income and an increased quarterly dividend, marking the 63rd...",
      "url": "https://finnhub.io/api/news?id=af0fe83484030cbe6511ab509f66026ce1c5ed43f4fb9c2bccae9aded3cfaff2"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved IMAAVY™ (nipocalimab-aahu), a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis (gMG). The approval, which follows FDA Priority Review designation, offers a new treatment option in a proven class with the potential for lasting disease control in the broadest population of people living with gMG (adults and pediatric patients 12 years of age and old",
    "url": "https://finnhub.io/api/news?id=be7f106d60e4a2163ab27b72a76315a35ad77dda4dde8e10c7f24c5281b71007",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746016140,
      "headline": "Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)",
      "id": 134165934,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved IMAAVY™ (nipocalimab-aahu), a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis (gMG). The approval, which follows FDA Priority Review designation, offers a new treatment option in a proven class with the potential for lasting disease control in the broadest population of people living with gMG (adults and pediatric patients 12 years of age and old",
      "url": "https://finnhub.io/api/news?id=be7f106d60e4a2163ab27b72a76315a35ad77dda4dde8e10c7f24c5281b71007"
    }
  },
  {
    "ts": null,
    "headline": "The Davenport Value & Income Fund Q1 2025 Commentary",
    "summary": "The Davenport Value & Income Fund generated a 3.83% total return in Q1 2025, outperforming the Russell 1000 ValueÂ® Index. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=96d3c7497f3ba63eec08c4af14f9777376153d1dbd6279bd521bdef95107b09d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746009000,
      "headline": "The Davenport Value & Income Fund Q1 2025 Commentary",
      "id": 134145461,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1598043982/image_1598043982.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The Davenport Value & Income Fund generated a 3.83% total return in Q1 2025, outperforming the Russell 1000 ValueÂ® Index. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=96d3c7497f3ba63eec08c4af14f9777376153d1dbd6279bd521bdef95107b09d"
    }
  }
]